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Abstract: This 8-week, multicenter study evaluated the efficacy and safety of candesartan
cilexetil (CC, 8–16 mg) in elderly (>65 years) hypertensive patients. Patients (n=3013) received
CC 8 mg during 8 weeks which eventually doubled to CC 16 mg at week 4 if blood pressure
remained uncontrolled (>140/90 mmHg). At week 8, 65.5% of patients were normalized (BP
<140/90 mmHg). Mean changes at week 8 were –25.8, –13.2, and –12.7 mmHg for systolic,
diastolic, and pulse pressure, respectively. Age, sex, and diabetic status did not influence the
antihypertensive effect of CC. 68% of the patients treated with, but uncontrolled or intolerant
of, prior antihypertensive treatment were normalized by CC 8–16 mg. In summary, CC 8–
16 mg once daily was effective and well tolerated in the management of arterial hypertension
in elderly subjects.
Keywords: candesartan cilexetil, angiotensin II receptor antagonist, hypertension, elderly
subject, CHANCE study
Introduction
Hypertension is the most prevalent epidemic disease with a major impact on morbidity
and mortality in the current world. Its prevalence is increasing in the adult population,
and is estimated to be 30% in developed countries (Asmar et al 2001; ESH 2003).
With increasing longevity, there is a shift from diastolic to systolic high blood
pressure (BP). Diastolic BP (DPB) increases until about the age of 60, whereas systolic
BP (SBP) continues to rise with age (Vasan et al 2002). Isolated systolic hypertension
affects 10%–20% of the elderly and becomes the predominant type of hypertension
(nearly 60%) in both treated and untreated elderly subjects (Chobanian et al 2003;
Thijs et al 2004). In older patients with isolated systolic hypertension there is an
increased risk of developing cardiovascular disease. Clinical trials have demonstrated
that control of isolated systolic hypertension reduces global mortality, cardiovascular
mortality, stroke, and heart failure events (Chobanian et al 2003). Randomized studies
have demonstrated that treating hypertensive older persons is useful in decreasing
mortality and morbidity (Mulrow et al 1994). There is strong evidence from clinical
trials to support the treatment of systolic hypertension in older person with SBP of at
least 160 mmHg (Chaudhry et al 2004).
Despite this knowledge, there is an important gap between the number of
hypertensive patients and the percentage of normalized patients (Chaudhry et al 2004).
Two principal reasons could explain this gap: on the one hand, there is a poor patient
adherence to treatment, and on the other hand, physicians are not aggressive enough
in the management of hypertension (Berlowitz et al 1998). Therapeutic approaches
include increased doses of antihypertensive agents, the use of combination therapy,
or introduction of an alternative class of therapeutic agent.
Initial therapeutic approaches include beta-blockers, diuretics, angiotensin
converting enzyme (ACE) inhibitors, calcium channel blockers, angiotensin II receptor
antagonists, and low dose combinations (Reif et al 1998; HAS 2005).
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The development of angiotensin II receptor antagonists
represented an important advance in the treatment of
hypertension. Candesartan cilexetil (CC) is an angiotensin
II type 1 (AT1) receptor antagonist. In controlled clinical
trials, candesartan has proven to be effective in lowering
BP; its efficacy increases up to a dose of 32 mg po once
daily (Reif et al 1998; Meredith 2000; Neldam and Forsen
2001). The antihypertensive effect of CC in doses up to
16 mg/day has been confirmed (Elmfeldt et al 1997) with
acceptable tolerability in numerous patient groups, including
women, diabetics, and patients with severe hypertension
(Oparil et al 1999; Trenkwalder 2000).
Materials and methods
Patients
This study included outpatients, over 65 years old, with a
diagnosis of essential hypertension (SBP ≥140 mmHg and/
or DBP ≥90 mmHg). Hypertension was untreated, treated
with poor tolerability, or treated but not normalized. Patients
were enrolled by general practitioners in France.
The exclusion criteria were as follows: age <65 years;
orthostatic hypotension; poor tolerance to angiotensin II
inhibitors; secondary arterial hypertension; cardiac
arrhythmia; congestive cardiac failure; valvular stenosis;
ischemic cardiomyopathy or stenosis of a clinically
important cerebral artery; surgery or gastrointestinal
pathology potentially affecting the absorption or elimination
of the treatment study; severe renal or hepatic insufficiency.
Methodology
This 8-week, multicenter study evaluated the efficacy and
tolerability of CC in treating elderly hypertensive patients.
During the study, the investigator examined the patient at three
visits: at inclusion, and after 4 and 8 weeks of treatment. At
inclusion, all patients were given CC at a dose of 8 mg once
daily. If BP remained uncontrolled (SBP ≥140 and/or DBP
≥90 mmHg) at week 4, CC was increased to 16 mg once a day.
If BP was controlled at week 4, patients remained on CC 8 mg
for an additional 4 weeks.
The study was conducted according to the Declaration
of Helsinki for biomedical research. The protocol was
approved by the French Independent Ethics Committee (IE).
Written informed consent was obtained from each patient.
Efficacy and safety criteria
The primary efficacy endpoint was the proportion of patients
normalized (BP <140/90 mmHg) by CC at the end of week
8. The secondary efficacy criteria were the proportions of
patients normalized at week 4, and the mean BP changes
from baseline to week 4 and week 8.
Sitting BP was measured according to guidelines
(O’Brien et al 2003) from the dominant arm (arm with the
higher SBP) 3 times at 2-minute intervals after the patient
had been sitting for at least 5 minutes.
Cardiovascular risk was calculated following ESH
guidelines (ESH 2003). Safety was assessed by monitoring
the incidence of adverse events during the treatment period,
whether reported as related or unrelated to the use of CC.
In addition, orthostatic hypotension was surveyed.
Statistical analysis
Efficacy was determined for an intent-to-treat (ITT)
population which included all patients who took at least
one dose of treatment and for whom the baseline BP value
was available. Per-protocol (PP) population consisted of all
patients from the ITT population not presenting major
protocol deviations. Qualitative variables were compared
using the Chi-square test. Groups were compared by analysis
of variance (ANOVA). A p value ≤0.05 was considered
statistically significant.
Results
Patient
A total of 3077 patients were included in the study. Among
them, 64 patients were excluded from the analysis (no
treatment intake and/or missing BP values at baseline).
During follow-up, 2884 patients (95.7%) completed the
study, and 129 patients (4.3%) withdrew prematurely
(adverse events, n=28; protocol deviation, n=27; consent
withdrawal, n=13; lost to follow-up, n=13; not determined,
n=17; inefficacy, n=4; other reasons, n=27).
ITT population consisted of 3013 patients. At the end of
the study (week 8), 58% of patients had received CC 8/
8 mg (CC 8 mg the first 4 weeks followed by 8 mg the last 4
weeks), and 42% of patients received CC 8/16 mg (CC 8 mg
the first 4 weeks followed by 16 mg the last 4 weeks).
Demographics and baseline
characteristics
Baseline clinical characteristics of the patients are presented
in Table 1. The arterial hypertension was principally systolic
(99.8%). The mean ± SD hypertension duration was 4.7±6.5
years, with 43.5% of patients diagnosed during the last year
and 16.2% of patients diagnosed more than 10 years ago.Vascular Health and Risk Management 2006:2(3) 319
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Patients with grade I (SBP 140–159 mmHg or DBP 90–
99 mmHg), grade II (SBP 160–179 mmHg or DBP 100–
109 mmHg), and grade III (SBP ≥180 mmHg or DBP
≥110 mmHg) hypertension at entry was 27.7%, 61.2%, and
8.9%, respectively. Hypertension was previously treated in
59% of patients; previous antihypertensive therapy was
diuretics (28.6%), calcium inhibitors (23.6%), ACE
inhibitors (18.6%), and beta-blockers (8.5%). 85% of
patients switched to CC 8 mg because of poor therapeutic
response to previous therapy. 99.4% of patients had at least
one cardiovascular risk factor.
Antihypertensive effect of candesartan
cilexetil
BP normalization
The target of SBP <140 mmHg and DBP <90 mmHg was
achieved at week 4 by 1267 patients (42.9%) and at week 8
by 1865 patients (65.5%) (Figure 1). The dose adjustment
at week 4 from CC 8 mg to CC 16 mg increased the
proportion of responders for both SBP/DBP <140/90 mmHg
by 22.6%. Among the patients not responding to CC 8 mg
at week 4, 47.9% of patients responded when treated by
CC 16 mg. With reference to a target of SBP/DBP <150/
90 mmHg, 69% and 88.8% of patients were normalized at
week 4 and week 8 respectively (Figure 1A). Similar results
with higher proportions of normalized patients were
observed in the PP population analysis: the target of SBP/
DBP <140/90 mmHg was achieved by 53.4% and 70.5% at
week 4 and week 8, respectively.
BP responders
At the end of the study, 83.7% patients showed a clinically
significant response (SBP <140 mmHg or reduction of
20 mmHg compared with the baseline value and DBP
Table 1 Baseline characteristics of patients
Characteristics Total
Age (years)
a 73±7
Sex (female)
b 1696 (56.4)
BMI (kg/m
2)
a 26.6±4.2
Isolated systolic HTA
b 3006 (99.8)
Treated by an anti-hypertensive treatment 1769 (59.0)
Duration of hypertension (years)
a 4.7±6.5
Systolic BP (mmHg) 163±11
Diastolic BP (mmHg) 92±8
Heart rate (bpm) 75±8
Pulsed pressure (mmHg) 71±11
Major cardiovascular risk factors
b
Hypercholesterolemia
c 1019 (33.8)
Current smokers 377 (12.5)
Organ damage 372 (12.3)
Diabetes
d 278 (9.2)
Abdominal obesitye 940 (31.2)
Familial history of cardiovascular disease  678 (22.5)
Risk factors numbers/patient
a 2.9±1.2
Level of cardiovascular riskb
Mild 7 (0.2)
Moderate 1056 (35.8)
High 1619 (54.9)
Very high 267  (9.1)
Not available 64 (2.1)
a Mean ± SD
b N(%): absolute number (percentage)
c Hypercholesterolemia (HDL-cholesterol <0.35 g/L (0.9 mmol/L); LDL-
cholesterol >1.90 g/L (4.9 mmol/L)
d Diabetes was defined by the presence of anti-diabetic treatment
e Abdominal obesity was assessed by a yes/no question
69%
42,9%
88,8%
65,5%
0
10
20
30
40
50
60
70
80
90
100
<140/90  mm Hg <150/90 mm Hg
p
e
r
c
e
n
t
a
g
e
 
o
f
 
p
a
t
i
e
n
t
s
 
w
i
t
h
 
n
o
r
m
a
l
i
z
e
d
 
B
P
Week 4 Week 8
74,2%
61,6%
91,9%
83,7%
0
10
20
30
40
50
60
70
80
90
100
<140/90 mm Hg <150/90 mm Hg
p
e
r
c
e
n
t
a
g
e
 
o
f
 
r
e
s
p
o
n
d
e
r
 
p
a
t
i
e
n
t
s
Week 4 Week 8
A
B 
Figure 1 Patients with normalized blood pressure (BP) (A) and responders (B)
to candesartan cilexetil (CC) (8–16 mg) at week 4 and week 8. Patients were
considered as normalized according to two systolic (S) and diastolic (D) BP
targets: SBP/DBP <140/90 mmHg, and SBP/DBP <150/90 mmHg. Patients were
considered as responders if they achieved SBP <140 mmHg or a reduction of
20 mmHg on the SBP compared with the baseline value and DBP <90 mmHg or
a reduction of 10 mmHg on the DBP compared with the baseline value. Two BP
targets were evaluated: SBP/DBP <140/90 mmHg, and SBP/DBP <150/90 mmHg.
Week 4, n=2951 and week 8, n=2847. At week 8, 1659 patients received CC 8/
8 mg and 1187 patients received CC 8/16 mg.Vascular Health and Risk Management 2006:2(3) 320
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<90 mmHg or reduction of 10 mmHg compared with the
baseline value) (Figure 1B). Comparable results were
observed in the PP population: the target was achieved by
63.8% and 85.6% at week 4 and week 8, respectively.
BP reduction
BP values showed a significant decrease at week 4 following
CC 8 mg treatment. The changes over time in SBP, DBP,
and PP values are shown in Table 2. The most important
change occurred between baseline and week 4 (SBP/DBP:
–21/–10 mmHg); BP values continued to decrease up to
week 8 (SBP/DBP: –26/–13 mmHg). Patients not
normalized at week 4 by CC 8 mg, and in whom the dose of
CC was increased to 16 mg, showed a decrease in their SBP/
DBP values of –11/–6 mmHg at week 8.
BP control was inversely related to the degree of
hypertension at baseline. Hypertensive patients of grade I,
grade II, and grade III were normalized at week 4 in 57.5%,
37.1%, and 27.9% of cases, respectively, and at week 8 in
75.5%, 62.6%, and 47.4% of the cases, respectively.
Previous antihypertensive therapy at baseline did not
influence the percentage of normalized patients (68% and
64.1% for treated and untreated, respectively) at the end of
the study. Despite different SBP baseline values between
previously treated vs untreated patients (161±11 and
164±11 mmHg, p<0.001) no differences were found after
treatment (136±9 and 137±9 mmHg, treated vs untreated
patients).
Antihypertensive effect of CC
according to previous treatment, age,
sex, and diabetes
After 8 weeks of treatment with CC, significant decreases
of SBP were observed for all patients, a mean of 136 mmHg
with 95% confidence interval ranging from 135 to
138 mmHg, irrespective of previous treatment (Figure 2).
Variation of SBP and DBP were similar for men and
women. Neither age (≤80 or >80 years of age) nor diabetes
were related to the antihypertensive effect of CC 8–16 mg
(Table 3).
Table 2 Mean blood pressure (BP) values (mean ± SD) at baseline, and after 4 weeks and 8 weeks of candesartan cilexetil (CC)
Week 4 Week 8
Baseline CC 8mg Total CC 8mg CC 16mg
Systolic BP (mmHg) 163±11 142±11 137±9 134±7 141±10
Diastolic BP (mmHg) 92± 8 82±8 79±7 78±6 81±7
Pulse pressure (mmHg) 71±11 60±10 58±8 56±7 60±9
Heart rate (bpm) 75±8 73±7 73±7 72±7 73±7
130 
Diuretics 
Calcium channel antagonists
ACE inhibitors 
Beta blockers 
mm HG 
140 150 160
Week 8 Baseline
Figure 2 Effect of candesartan cilexetil on systolic blood pressure according to previous antihypertensive treatment. Values are presented as confidence interval 95%.
Abbreviations: ACE, angiotensin converting enzyme.
mmHgVascular Health and Risk Management 2006:2(3) 321
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Safety results
A total of 219 adverse events (AEs) were reported by 174
patients (5.8%). 51 AEs experienced by 49 patients (1.6%)
were considered. 36 AEs resulted in discontinuation in 28
patients (0.9%); 2 of these were severe AEs (breast cancer
and severe arterial hypotension). The most common AEs
resulting in study discontinuation were vertigo (n=5), rash
(n=4), headache (n=3), and nausea (n=2).
Orthostatic hypotension was reported in 4 patients
(0.1%) at week 4 and 3 patients (0.1%) at week 8.
Discussion
Treatment of hypertensive patients may be considered to
be the achievement of SBP/DBP <140/90 mmHg (Reif et al
1998; HAS 2005). This study demonstrated that CC is an
effective treatment for BP control in elderly patients (aged
>65 years). Administration of CC 8 mg for 4 weeks and
doubling CC dose if the patients did not achieve BP
normalization resulted in 65.5% of patients being normalized
after 8 weeks of treatment.
At baseline, 59% of patients were already treated by one
antihypertensive treatment (28.6% diuretics, 23.6% calcium
channel blockers, 18.6% ACE inhibitors, and 8.5% beta-
blockers). The results observed in these elderly hypertensive
patients corroborate those observed with similar studies
performed in middle-aged populations. A European
multicenter study showed that switching to angiotensin II
receptor blocker (ARB) treatment (candesartan 8–16 mg
once daily) was associated with a significant decrease of
BP with a higher percentage of responders (Asmar et al
2004). An analysis of the patient subgroup aged >65 years
of age in the Switch study (n=236) showed that BP benefit
was observed irrespective of age or to previous treatment
(Asmar et al 2004).
In patients aged over 60 years, systolic hypertension is
a more important cardiovascular disease risk factor than
diastolic hypertension. Consequently the control of SBP
should be the focus of treatment in this population
(Chobanian et al 2003; HAS 2005).
In the present study population, hypertension was
principally systolic (99.8% of the patients).
SBP values decreased by an average of 25.8 mmHg.
Studies have shown that a small decrease in mean SBP has
benefit in terms of cardiovascular morbidity and mortality
(Turnbull 2003). Antihypertensive treatment has
demonstrated efficacy in primary prevention of cardiac
events and stroke in high-risk patients >60 years of age,
particularly by lowering SBP (Dahlof et al 1991; SHEP
1991; Staessen et al 1997; Andrawes et al 2005). A recent
study conducted by the Study on Cognition and Prognosis
in the Elderly Group (Trenkwalder et al 2005) indicated a
reduction in major cardiovascular events and stroke in
elderly people (70–89 years) treated with candesartan.
One objective of treating elderly subjects (more than 80
years old) is to achieve SBP <150 mmHg in the absence of
orthostatic hypotension (HAS 2005). Thomas et al (2006)
highlighted the benefit of ARBs in elderly patients with
hypertension. In this study, 88.2% of patients were
normalized <150 mmHg after being treated for 8 weeks with
candesartan 8–16 mg. Orthostatic hypotension was rarely
observed (0.1%).
During the last decade, the role of high pulse pressure
as an independent marker of cardiovascular morbidity and
mortality has been largely described in both treated and
untreated hypertensive patients aged over 50 years. Anti-
hypertensive agents have varying effects. ARBs decrease
high pulse pressure in hypertensive patients. These results
demonstrated a significant reduction of 13 mmHg for PP,
Table 3 Influence of age, sex, and diabetes on the systolic and diastolic blood pressure (SBP, DBP) changes (mean ± SD) of patients
treated with candesartan cilexetil (CC)
Patients Baseline Week 4 Week 8
N (%) SBP DBP SBP DBP SBP DBP
(mmHg) (mmHg) (mmHg) (mmHg) (mmHg) (mmHg)
Age (years)    
<80 2535 (84) 162±11 92±8 142±11 82±8 137±9 79±7
≥80 470 (16) 164±11 91±8 143±12 81±8 137±10 78±6
Sex
Female 1696 (56)  163±11 92±8 142±11 82± 8 137±9 78±7
Male 1313 (44) 162±11 93±8 142±11 82±8 137±9 79±7
Diabetes
Present 278 (9) 162±12 92±8 143±12 82±8 137±10 80±6
Absent 2735 (91) 163±11 92±8 142±11 82±8 137±9 79±7Vascular Health and Risk Management 2006:2(3) 322
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which confirm previous studies in hypertensive patients
(Vaccarino et al 2001).
Hypertension is often associated other risk factors (sex,
age, diabetes). In the present study, the SBP values at
baseline demonstrated a significant difference according to
age (<80 vs ≥80 years, p=0.004) and with the existence of a
previous antihypertensive treatment (treated vs untreated,
p<0.001). After 8 weeks of treatment with CC, no subgroup
differences were found for the final BP values (sex, age,
diabetes). The results are interesting to compare with the
ALLHAT study, where predictive factors for
antihypertensive treatment inefficacy included female sex
and diabetes (Cushman et al 2002). In the LIFE study,
diabetic patients needed more medication than non diabetics
for hypertension (Kjeldsen et al 2000). In this study the key
factor to predict normalization of both SBP and DBP was
the severity of hypertension.
Elderly subjects have an increased susceptibility to
adverse reactions from pharmacological treatment. All
subjects participating in the present study were more than
65 years old, 470 subjects (16%) were over 80 years old. In
this study 1.6% of patients developed an AE related to the
treatment and 0.9% discontinued the study. The most
common AEs resulting in study discontinuation were
vertigo, rash, headache, and nausea. These results suggest
that CC is generally tolerated in elderly patients with an
acceptable safety profile (Trenkwalder 2000; Neldam and
Forsen 2001; Skoog et al 2005). A limitation of the present
study is that it was not a controlled study, and it was
conducted in general practice.
In conclusion, this large-scale study in elderly
hypertensive patients in France, demonstrated that
candesartan (8–16 mg once daily) is suitable therapy for
effective control of blood pressure and enhanced patient
compliance.
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